43 results
SC TO-T/A
EX-99
KNTE
Kinnate Biopharma Inc
19 Mar 24
Third party tender offer statement (amended)
4:44pm
of Sail Bio, Inc., a private biotechnology company focused on addressing toxic proteinopathies, since February 2022 and served as the Chief Executive
SC TO-T
EX-99
KNTE
Kinnate Biopharma Inc
4 Mar 24
Third party tender offer statement
5:24pm
served as the Chief Executive Officer of Sail Bio, Inc., a private biotechnology company focused on addressing toxic proteinopathies, since February 2022
8-K
EX-10.1
hqiez xid0d2bpdy860t
5 Aug 21
Entry into a Material Definitive Agreement
5:06pm
8-K
EX-1.1
utt th67r45zr4qyo
8 Apr 21
Results of Operations and Financial Condition
4:43pm
8-K
EX-1.1
dtledo gptb
11 Dec 20
Entry into a Material Definitive Agreement
5:27pm
8-K
EX-10.1
7fl1eqput7u1mbu6m4n2
18 Dec 18
Entry into a Material Definitive Agreement
4:46pm
8-K
EX-1.1
uv7yy0im0mcbi8 6n7mj
9 Dec 14
XOMA Announces Pricing of $40.0 Million Registered Offering of Common Stock and Warrants
12:00am
8-K
EX-1.1
40iwh9a7zwg x3grjq
13 Dec 13
Other Events
12:00am
8-K
EX-1.1
ob5fay xl1i
24 Oct 12
Other Events
12:00am